Significant ETF Inflows: SPYM, JNJ, ABBV, AMD
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 14 2025
0mins
Should l Buy ABBV?
Source: NASDAQ.COM
SPYM Share Price Analysis: SPYM's 52-week low is $56.6699 and high is $81.135, with the last trade recorded at $78.65, indicating a stable position within its range.
Understanding ETFs: Exchange-traded funds (ETFs) function like stocks, where investors buy and sell "units" that can be created or destroyed based on demand, impacting the underlying assets.
Monitoring ETF Flows: Weekly analysis of shares outstanding helps identify ETFs with significant inflows (new units created) or outflows (units destroyed), which can affect the individual components of the ETFs.
Disclaimer on Views: The opinions expressed in the article are those of the author and do not necessarily represent the views of Nasdaq, Inc.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABBV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABBV
Wall Street analysts forecast ABBV stock price to rise
18 Analyst Rating
12 Buy
6 Hold
0 Sell
Moderate Buy
Current: 206.470
Low
223.00
Averages
252.00
High
289.00
Current: 206.470
Low
223.00
Averages
252.00
High
289.00
About ABBV
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
IMGN853-0420 Trial Shows Efficacy of New Treatment
- Clinical Trial Results: The IMGN853-0420 trial demonstrated a 62.7% objective response rate (ORR) in patients with ≥50% folate receptor alpha (FRα) expression, indicating significant efficacy of mirvetuximab soravtansine-gynx combined with carboplatin, potentially offering a new treatment option for ovarian cancer patients.
- Patient Population Analysis: This multicenter, open-label study enrolled 125 patients, all of whom had received one prior platinum-based chemotherapy, with results showing that 81% of patients did not experience disease progression post-treatment, highlighting the sustained effectiveness of this regimen.
- Safety Assessment: The safety profile of mirvetuximab soravtansine-gynx was consistent with previous studies, with common adverse events being low-grade ocular reactions, over 90% of which were reversible, indicating good tolerability of the treatment.
- Future Research Directions: Investigators emphasized that the combination of mirvetuximab soravtansine-gynx with standard chemotherapy provides a novel treatment strategy for FRα-expressing recurrent platinum-sensitive ovarian cancer, with plans for further exploration of its application potential in other patient populations.
See More
Strong Performance Fuels Promising Growth Outlook
- Significant Revenue Growth: Johnson & Johnson reported a 9.9% year-over-year revenue increase in Q1, reaching $24.06 billion, surpassing the market expectation of $23.63 billion, which underscores the company's robust performance in pharmaceuticals and medical technology, further solidifying its market position.
- Adjusted EPS Exceeds Expectations: The adjusted earnings per share for the first quarter stood at $2.70, exceeding the anticipated $2.66, reflecting effective management in cost control and profitability, which enhances investor confidence.
- Strong New Drug Sales: Sales of the blood cancer therapy Darzalex rose 22.5% year-over-year to $3.96 billion, exceeding market expectations, while Tremfya sales surged 68% to $1.61 billion, showcasing Johnson & Johnson's competitiveness and market demand in innovative pharmaceuticals.
- Optimistic Future Growth Guidance: Johnson & Johnson raised its full-year guidance, projecting revenue growth between 5.9% and 6.9%, with adjusted EPS expectations increased to a range of $11.45 to $11.65, indicating the company's confidence in future performance and positive market outlook.
See More
AbbVie Ventures into Weight Loss Market with Promising Drug
- Clinical Trial Results: AbbVie's March 9 announcement of ABBV-295's clinical trial results indicates that patients receiving weekly treatment lost an average of 7.75% to 9.79% of their weight over 12 weeks, while those on biweekly or monthly regimens lost between 7.86% and 9.73% over 13 weeks, suggesting strong potential for the drug in the weight loss market.
- Competitive Market Pressure: Despite the promising initial data for ABBV-295, AbbVie faces intense competition in the weight loss market from companies like Eli Lilly, which have several late-stage obesity drugs, indicating that the market will become increasingly crowded before AbbVie can launch its product.
- Core Business Stability: AbbVie's primary therapeutic area remains immunology, with projected sales for Skyrizi and Rinvoq exceeding $31 billion in 2023, significantly surpassing Humira's peak sales, demonstrating the company's robust performance and growth potential in this sector.
- Optimistic Pipeline Outlook: Even if ABBV-295 fails in clinical trials, AbbVie has a deep pipeline of investigational products, including the ongoing ABBV-383 cancer treatment, which is expected to provide significant support for the company's future financial performance and further solidify its leadership in the pharmaceutical industry.
See More
Allergan Aesthetics Partners with Erin Lichy to Promote Transparency in Aesthetic Procedures
- Celebrity Partnership: Allergan Aesthetics collaborates with New York entrepreneur and TV personality Erin Lichy to promote transparency in aesthetic procedures by sharing her breast augmentation journey, aiming to help more women understand their surgical options.
- Personal Story Sharing: As a mother of four, Lichy's decision for breast augmentation after breastfeeding highlights the importance of body positivity, and she shares her surgical experience on social media to encourage other women to explore their choices.
- Commitment to Product Safety: Natrelle® breast implants come with a 10-year clinical safety profile, focusing on providing clear and credible information to ensure women can make informed decisions when considering surgery.
- Patient Education Initiative: Natrelle® launches the “Faces of Natrelle®” program, inviting women who have undergone breast augmentation to share their experiences, further promoting transparent dialogue and strengthening the connection between the brand and consumers.
See More
Vicious Cycle Index Signals Economic Recession
- Vicious Cycle Index Overview: Moody's Analytics' Vicious Cycle Index (VCI) has accurately predicted 100% of U.S. recessions over the past 80 years without a single false alarm, demonstrating its effectiveness and reliability in economic forecasting.
- Unemployment Rate Indicator: The VCI is based on the Sahm Rule, which requires the three-month average unemployment rate to exceed the 12-month low by 1%, enhancing its accuracy in capturing recessions, especially in the context of declining labor force participation.
- Current Economic Condition: Chief economist Mark Zandi of Moody's Analytics believes that the U.S. economy has already entered a recession, despite the National Bureau of Economic Research not yet confirming it, with the probability of recession rising to 48.6%, surpassing predictions from other organizations.
- Investment Strategy Recommendations: Investors should consider purchasing recession-proof stocks such as Walmart, AbbVie, and American States Water, which tend to perform well during economic downturns, while also maintaining cash reserves to capitalize on potential investment opportunities.
See More
Vicious Cycle Index Warns of U.S. Recession
- Recession Signal: The Vicious Cycle Index (VCI) has accurately predicted all U.S. recessions since 1945 and currently indicates that the U.S. economy is in the early stages of a recession, prompting investors to adjust their strategies based on this critical indicator.
- Unemployment Rate Changes: The VCI improves upon the Sahm Rule by adjusting unemployment data using a five-year moving average of labor force participation, signaling a recession when the average unemployment rate rises more than 1% over the previous 12 months, enhancing its accuracy.
- Investment Strategy Recommendations: With rising recession risks, investors are advised to increase cash positions and consider buying recession-resistant stocks such as Walmart, AbbVie, and American States Water, which are likely to maintain stable dividend payments during economic downturns.
- Declining Market Confidence: Consumer confidence hit a record low in April, and the labor force participation rate fell to 61.9%, indicating that more Americans are giving up on job searches; Moody's Analytics raised the probability of a recession in the next 12 months to 48.6%, surpassing other organizations' forecasts.
See More
IMGN853-0420 Trial Shows Efficacy of New Treatment
- Clinical Trial Results: The IMGN853-0420 trial demonstrated a 62.7% objective response rate (ORR) in patients with ≥50% folate receptor alpha (FRα) expression, indicating significant efficacy of mirvetuximab soravtansine-gynx combined with carboplatin, potentially offering a new treatment option for ovarian cancer patients.
- Patient Population Analysis: This multicenter, open-label study enrolled 125 patients, all of whom had received one prior platinum-based chemotherapy, with results showing that 81% of patients did not experience disease progression post-treatment, highlighting the sustained effectiveness of this regimen.
- Safety Assessment: The safety profile of mirvetuximab soravtansine-gynx was consistent with previous studies, with common adverse events being low-grade ocular reactions, over 90% of which were reversible, indicating good tolerability of the treatment.
- Future Research Directions: Investigators emphasized that the combination of mirvetuximab soravtansine-gynx with standard chemotherapy provides a novel treatment strategy for FRα-expressing recurrent platinum-sensitive ovarian cancer, with plans for further exploration of its application potential in other patient populations.
See More
Strong Performance Fuels Promising Growth Outlook
- Significant Revenue Growth: Johnson & Johnson reported a 9.9% year-over-year revenue increase in Q1, reaching $24.06 billion, surpassing the market expectation of $23.63 billion, which underscores the company's robust performance in pharmaceuticals and medical technology, further solidifying its market position.
- Adjusted EPS Exceeds Expectations: The adjusted earnings per share for the first quarter stood at $2.70, exceeding the anticipated $2.66, reflecting effective management in cost control and profitability, which enhances investor confidence.
- Strong New Drug Sales: Sales of the blood cancer therapy Darzalex rose 22.5% year-over-year to $3.96 billion, exceeding market expectations, while Tremfya sales surged 68% to $1.61 billion, showcasing Johnson & Johnson's competitiveness and market demand in innovative pharmaceuticals.
- Optimistic Future Growth Guidance: Johnson & Johnson raised its full-year guidance, projecting revenue growth between 5.9% and 6.9%, with adjusted EPS expectations increased to a range of $11.45 to $11.65, indicating the company's confidence in future performance and positive market outlook.
See More
AbbVie Ventures into Weight Loss Market with Promising Drug
- Clinical Trial Results: AbbVie's March 9 announcement of ABBV-295's clinical trial results indicates that patients receiving weekly treatment lost an average of 7.75% to 9.79% of their weight over 12 weeks, while those on biweekly or monthly regimens lost between 7.86% and 9.73% over 13 weeks, suggesting strong potential for the drug in the weight loss market.
- Competitive Market Pressure: Despite the promising initial data for ABBV-295, AbbVie faces intense competition in the weight loss market from companies like Eli Lilly, which have several late-stage obesity drugs, indicating that the market will become increasingly crowded before AbbVie can launch its product.
- Core Business Stability: AbbVie's primary therapeutic area remains immunology, with projected sales for Skyrizi and Rinvoq exceeding $31 billion in 2023, significantly surpassing Humira's peak sales, demonstrating the company's robust performance and growth potential in this sector.
- Optimistic Pipeline Outlook: Even if ABBV-295 fails in clinical trials, AbbVie has a deep pipeline of investigational products, including the ongoing ABBV-383 cancer treatment, which is expected to provide significant support for the company's future financial performance and further solidify its leadership in the pharmaceutical industry.
See More
Allergan Aesthetics Partners with Erin Lichy to Promote Transparency in Aesthetic Procedures
- Celebrity Partnership: Allergan Aesthetics collaborates with New York entrepreneur and TV personality Erin Lichy to promote transparency in aesthetic procedures by sharing her breast augmentation journey, aiming to help more women understand their surgical options.
- Personal Story Sharing: As a mother of four, Lichy's decision for breast augmentation after breastfeeding highlights the importance of body positivity, and she shares her surgical experience on social media to encourage other women to explore their choices.
- Commitment to Product Safety: Natrelle® breast implants come with a 10-year clinical safety profile, focusing on providing clear and credible information to ensure women can make informed decisions when considering surgery.
- Patient Education Initiative: Natrelle® launches the “Faces of Natrelle®” program, inviting women who have undergone breast augmentation to share their experiences, further promoting transparent dialogue and strengthening the connection between the brand and consumers.
See More
Vicious Cycle Index Signals Economic Recession
- Vicious Cycle Index Overview: Moody's Analytics' Vicious Cycle Index (VCI) has accurately predicted 100% of U.S. recessions over the past 80 years without a single false alarm, demonstrating its effectiveness and reliability in economic forecasting.
- Unemployment Rate Indicator: The VCI is based on the Sahm Rule, which requires the three-month average unemployment rate to exceed the 12-month low by 1%, enhancing its accuracy in capturing recessions, especially in the context of declining labor force participation.
- Current Economic Condition: Chief economist Mark Zandi of Moody's Analytics believes that the U.S. economy has already entered a recession, despite the National Bureau of Economic Research not yet confirming it, with the probability of recession rising to 48.6%, surpassing predictions from other organizations.
- Investment Strategy Recommendations: Investors should consider purchasing recession-proof stocks such as Walmart, AbbVie, and American States Water, which tend to perform well during economic downturns, while also maintaining cash reserves to capitalize on potential investment opportunities.
See More
Vicious Cycle Index Warns of U.S. Recession
- Recession Signal: The Vicious Cycle Index (VCI) has accurately predicted all U.S. recessions since 1945 and currently indicates that the U.S. economy is in the early stages of a recession, prompting investors to adjust their strategies based on this critical indicator.
- Unemployment Rate Changes: The VCI improves upon the Sahm Rule by adjusting unemployment data using a five-year moving average of labor force participation, signaling a recession when the average unemployment rate rises more than 1% over the previous 12 months, enhancing its accuracy.
- Investment Strategy Recommendations: With rising recession risks, investors are advised to increase cash positions and consider buying recession-resistant stocks such as Walmart, AbbVie, and American States Water, which are likely to maintain stable dividend payments during economic downturns.
- Declining Market Confidence: Consumer confidence hit a record low in April, and the labor force participation rate fell to 61.9%, indicating that more Americans are giving up on job searches; Moody's Analytics raised the probability of a recession in the next 12 months to 48.6%, surpassing other organizations' forecasts.
See More
